In addition, the m6A regulator IGF2BP3 was associated with reduced cell apoptosis, larger tumor sizes, higher grade, higher clinical stage, necrosis, and CK5/6 expression and further worsened the DFS and OS of BC patients [4, 15, 16]. This evidence concerns the gene IGF2BP3 and breast cancer.